Anixa Biosciences (ANIX) Competitors $3.08 -0.07 (-2.22%) Closing price 03/27/2025 04:00 PM EasternExtended Trading$3.13 +0.05 (+1.75%) As of 03/27/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ANIX vs. ALLO, ARCT, RVNC, ABVX, HUMA, AURA, RAPP, RNAC, TSHA, and ATXSShould you be buying Anixa Biosciences stock or one of its competitors? The main competitors of Anixa Biosciences include Allogene Therapeutics (ALLO), Arcturus Therapeutics (ARCT), Revance Therapeutics (RVNC), ABIVAX Société Anonyme (ABVX), Humacyte (HUMA), Aura Biosciences (AURA), Rapport Therapeutics (RAPP), Cartesian Therapeutics (RNAC), Taysha Gene Therapies (TSHA), and Astria Therapeutics (ATXS). These companies are all part of the "pharmaceutical products" industry. Anixa Biosciences vs. Allogene Therapeutics Arcturus Therapeutics Revance Therapeutics ABIVAX Société Anonyme Humacyte Aura Biosciences Rapport Therapeutics Cartesian Therapeutics Taysha Gene Therapies Astria Therapeutics Allogene Therapeutics (NASDAQ:ALLO) and Anixa Biosciences (NASDAQ:ANIX) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, community ranking, media sentiment, earnings, institutional ownership, analyst recommendations, risk, valuation and profitability. Does the media prefer ALLO or ANIX? In the previous week, Anixa Biosciences had 15 more articles in the media than Allogene Therapeutics. MarketBeat recorded 22 mentions for Anixa Biosciences and 7 mentions for Allogene Therapeutics. Allogene Therapeutics' average media sentiment score of 1.13 beat Anixa Biosciences' score of 0.17 indicating that Allogene Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Allogene Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Anixa Biosciences 1 Very Positive mention(s) 4 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 2 Very Negative mention(s) Neutral Do analysts rate ALLO or ANIX? Allogene Therapeutics currently has a consensus price target of $9.29, indicating a potential upside of 495.44%. Anixa Biosciences has a consensus price target of $9.00, indicating a potential upside of 192.21%. Given Allogene Therapeutics' higher probable upside, equities research analysts clearly believe Allogene Therapeutics is more favorable than Anixa Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Allogene Therapeutics 0 Sell rating(s) 1 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 2.90Anixa Biosciences 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.25 Does the MarketBeat Community favor ALLO or ANIX? Allogene Therapeutics received 253 more outperform votes than Anixa Biosciences when rated by MarketBeat users. However, 75.61% of users gave Anixa Biosciences an outperform vote while only 65.89% of users gave Allogene Therapeutics an outperform vote. CompanyUnderperformOutperformAllogene TherapeuticsOutperform Votes28465.89% Underperform Votes14734.11% Anixa BiosciencesOutperform Votes3175.61% Underperform Votes1024.39% Which has higher earnings & valuation, ALLO or ANIX? Anixa Biosciences has higher revenue and earnings than Allogene Therapeutics. Anixa Biosciences is trading at a lower price-to-earnings ratio than Allogene Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAllogene Therapeutics$22K15,406.06-$327.27M-$1.33-1.17Anixa Biosciences$210K472.22-$12.55M-$0.39-7.90 Do institutionals & insiders believe in ALLO or ANIX? 83.6% of Allogene Therapeutics shares are held by institutional investors. Comparatively, 29.1% of Anixa Biosciences shares are held by institutional investors. 24.3% of Allogene Therapeutics shares are held by insiders. Comparatively, 25.3% of Anixa Biosciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Which has more volatility and risk, ALLO or ANIX? Allogene Therapeutics has a beta of 1.02, meaning that its share price is 2% more volatile than the S&P 500. Comparatively, Anixa Biosciences has a beta of 0.86, meaning that its share price is 14% less volatile than the S&P 500. Is ALLO or ANIX more profitable? Allogene Therapeutics' return on equity of -52.13% beat Anixa Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Allogene TherapeuticsN/A -52.13% -41.29% Anixa Biosciences N/A -58.55%-53.29% SummaryAllogene Therapeutics beats Anixa Biosciences on 10 of the 18 factors compared between the two stocks. Remove Ads Get Anixa Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for ANIX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ANIX vs. The Competition Export to ExcelMetricAnixa BiosciencesPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$99.17M$6.91B$5.64B$8.06BDividend YieldN/A2.73%4.57%4.01%P/E Ratio-7.907.2023.1419.03Price / Sales472.22226.01384.1193.17Price / CashN/A65.6738.1634.64Price / Book5.226.476.954.33Net Income-$12.55M$141.90M$3.20B$247.06M7 Day Performance-2.53%-3.20%-2.28%-0.37%1 Month Performance-2.22%-5.64%2.88%-3.85%1 Year Performance-1.28%-7.47%10.87%1.27% Anixa Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ANIXAnixa Biosciences3.1823 of 5 stars$3.08-2.2%$9.00+192.2%-4.6%$99.17M$210,000.00-7.905Analyst ForecastAnalyst RevisionNews CoverageGap UpALLOAllogene Therapeutics3.2377 of 5 stars$1.85-4.6%$9.40+408.1%-65.0%$387.89M$22,000.00-1.19310Positive NewsARCTArcturus Therapeutics2.7645 of 5 stars$14.16+0.6%$59.20+318.1%-63.5%$384.02M$138.39M-6.38180Positive NewsRVNCRevance Therapeutics2.0128 of 5 stars$3.65flat$8.39+129.7%N/A$381.02M$234.04M-1.89500Analyst ForecastABVXABIVAX Société Anonyme2.0608 of 5 stars$6.00+1.0%$38.67+544.4%-53.9%$380.30MN/A0.0061Analyst RevisionNews CoverageGap DownHigh Trading VolumeHUMAHumacyte2.1569 of 5 stars$3.01-1.0%$13.71+355.6%-35.2%$378.84M$1.57M-2.25150Analyst ForecastNews CoverageAURAAura Biosciences2.1682 of 5 stars$7.54+2.6%$23.00+205.0%-22.9%$376.63MN/A-4.3650Earnings ReportAnalyst RevisionNews CoverageHigh Trading VolumeRAPPRapport Therapeutics1.7376 of 5 stars$10.18-3.1%$35.00+243.8%N/A$371.53MN/A-0.74N/AShort Interest ↑RNACCartesian Therapeutics2.4042 of 5 stars$14.44-8.6%$42.14+191.8%-27.5%$366.99M$47.94M-0.2764Positive NewsTSHATaysha Gene Therapies2.761 of 5 stars$1.79+4.1%$6.63+270.1%-40.7%$366.95M$8.33M2.84180Positive NewsATXSAstria Therapeutics1.7843 of 5 stars$6.48+0.5%$26.67+311.5%-55.4%$365.69MN/A-3.1030Positive News Remove Ads Related Companies and Tools Related Companies Allogene Therapeutics Alternatives Arcturus Therapeutics Alternatives Revance Therapeutics Alternatives ABIVAX Société Anonyme Alternatives Humacyte Alternatives Aura Biosciences Alternatives Rapport Therapeutics Alternatives Cartesian Therapeutics Alternatives Taysha Gene Therapies Alternatives Astria Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ANIX) was last updated on 3/28/2025 by MarketBeat.com Staff From Our PartnersA $6.9 Trillion Cash Tsunami Is Coming – Move Your Money NOWExpert: "Prepare For the Mother of All Melt-Ups" In the wake of Wall Street volatility, stock-picking legen...Stansberry Research | SponsoredElon Warns: Exec Order 14024 Targets DollarExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | SponsoredAI Boom Takes a Shocking Turn…A potentially historic moment for retirement Let's make the most of this market together. Crypto 101 Media | SponsoredElon Musk is helping print “new gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredMost gold “analysts” aren’t really gold analysts… [watch out]People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Anixa Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Anixa Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.